Stay updated on Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.

Latest updates to the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page
- CheckyesterdayChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
- Check8 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check30 days agoChange DetectedThe latest update includes a revision of the study protocol, specifically noting that the Data Monitoring Committee is no longer applicable, and changes to participant assessments, including the discontinuation of electronic patient-reported outcome assessments and biomarker sample collections.SummaryDifference1%
- Check58 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference1%
Stay in the know with updates to Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.